Regenxbio is ranked Strong Buy due to low EV, strong partnerships, royalty income, bullish trends, and buyout potential.

Charles Schwab Investment Management Inc. reduced its stake in REGENXBIO Inc. (NASDAQ:RGNX – Free Report) by 16.3% in the 4th ...

Analysts at Chardan Capital reduced their FY2025 earnings estimates for shares of REGENXBIO in a research report issued to ...

Regenxbio (RGNX) came out with a quarterly loss of $1.01 per share versus the Zacks Consensus Estimate of a loss of $1.27. This compares to loss of $1.43 per share a year ago. These figures are ...

Cash Equivalents and Marketable Securities: $245 million as of December 31, 2024, down from $314 million as of December 31, 2023. R&D Expenses: $209 million for the year ended December 31, 2024 ...

Shares of several biotech and biopharma names are under pressure on Monday following the resignation of the head of the Food and Drug ...

Barclays analyst Gena Wang maintained a Buy rating on RegenXBio (RGNX – Research Report) yesterday and set a price target of $50.00. The company’s shares closed yesterday at $7.00. Easily identify ...

Regenxbio's RGX-202 gene therapy shows promising results in Duchenne muscular dystrophy, with high microdystrophin levels and ...